Anebulo Pharmaceuticals, Inc.

AI-generated fair value estimate for this company.

Method: Net-cash-plus-option-value method: $9.0M cash, risk-discounted ~50% for near-term dilution / going-concern risk given roughly one year of runway, plus an estimated $5M risk-adjusted pipeline option value for lead asset SVT-38ZERO (a CB1 antagonist for acute cannabinoid intoxication); 41.08M shares outstanding.

Reasoning: As a pre-revenue clinical-stage biotech with limited cash runway, Anebulo's value is dominated by its cash position and a modest option value on its single clinical program rather than a conventional cash-flow DCF.